Dyne Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for genetically driven neuromuscular diseases. The company utilizes its proprietary FORCE pla... Dyne Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for genetically driven neuromuscular diseases. The company utilizes its proprietary FORCE platform to deliver targeted RNA therapies designed to overcome delivery limitations to muscle tissue and the central nervous system. Dyne's lead programs address significant unmet medical needs in conditions including myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company is advancing multiple candidates through clinical development, with key programs progressing toward regulatory milestones and potential commercialization. Dyne operates in the rare disease biotechnology space, serving patients with limited treatment options and positioning itself for potential market entry as its pipeline candidates mature toward approval and launch.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Dyne Therapeutics is not subject to EU Taxonomy reporting

Based on current regulatory requirements, Dyne Therapeutics is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review Dyne Therapeutics's data?

Start your 30-day free trial to request a data review for Dyne Therapeutics.

Start Free Trial

Legal Center Contact Us

Dyne Therapeutics, Inc

Dyne Therapeutics is not subject to EU Taxonomy reporting

Account Restricted